阿扎西奥普林用于患有多发性硬化症的人
Ben Ridley1, Francesco Nonino1, Elisa Baldin1
1IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
The Cochrane database of systematic reviews
|December 9, 2024
概括
阿扎西奥普林可以适度减少多发性硬化症 (MS) 的复发,但对残疾有不确定的影响,并可能增加严重的不良事件. 由于证据的确定性较低,需要进行更多的研究.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性硬化症 (MS) 是中枢神经系统的一种慢性,炎症性,脱髓化的疾病,在全球范围内影响着280万人.
- 多发性硬化主要影响年轻女性,诊断的平均年龄为32岁,对健康造成重大负担.
- 用于自身免疫性疾病的阿扎西奥普林 (AZA) 是一种非标签治疗MS的药物,特别是在获得批准的疾病修饰治疗 (DMT) 的机会有限的地方.
研究的目的:
- 评估阿扎西奥普林 (AZA) 对复发性和渐进性多发性硬化症 (MS) 的益处和危害.
- 将AZA与其他DMT,安慰剂或没有治疗作为MS的首选或切换疗法进行比较.
- 评估关键结果,包括残疾,复发和严重不良事件 (SAE).
主要方法:
- 包括随机对照试验 (RCT) 和非随机干预研究 (NRSI) 在MS的成年人,持续至少12个月.
- 专注于AZA与其他DMT,安慰剂或不治疗复发性和进展性MS的比较.
- 收集关于残疾,复发,严重意外事件,生活质量和其他不良事件的数据.
主要成果:
- 与贝塔干扰素 (低确定性证据) 相比,阿扎西奥普林可能会减少复发性MS的复发.
- 与干扰素β相比,阿扎西奥普林对残疾进展和胃肠道疾病的影响的证据非常不确定.
- 与贝塔干扰素相比,阿扎西奥普林可能会增加严重不良事件 (SAE),尽管证据的确定性很低.
结论:
- 阿扎西奥普林在复发性多发性硬化症的复发频率上可能提供适度的益处,但与贝塔干扰素相比,可能会增加SAE.
- 关于阿扎西奥普林对残疾进展和短期不良事件的影响的证据非常不确定.
- 现有证据的确定性低至非常低,强调需要进一步研究,特别是对于渐进性多发性硬化和长期结果.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
01:29Inflammatory Bowel Disease IV: Pharmacological Management
112
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
112